Central Precocious Puberty Complicating Congenital Adrenal Hyperplasia: North Indian Experience
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sir, Increased androgen production often leads to peripheral precocious puberty (PPP) in congenital adrenal hyperplasia (CAH).[1] The chronic hyperandrogenemia may activate hypothalamic-pituitary axis and cause central precocious puberty (CPP) with advancement of bone age (BA) that compromises stature.[1] Short stature is indeed common in adults with CAH in less developed countries.[2] Gonadotropin-releasing hormone analogs (GnRHa) reduce the rate of linear growth and BA advancement and are considered an effective adjunct to steroids in the treatment of CPP complicating CAH.[3] However, data on GnRHa use are scarce from resource poor settings.[23] Of the 55 patients diagnosed as precocious puberty (PP), five (four girls and one boy) treated as CPP complicating CAH between 2007 and 2016 were retrospectively reviewed. Four had simple virilizing CAH whereas one had classic salt-wasting form. The diagnosis of CPP was based on either basal serum LH of ≥ 0.3 IU/L or peak stimulated LH ≥5.0 IU/L. The presenting features were premature breast or pubic hair development in girls and testicular enlargement in boy. The mean chronological age (CA) at onset of PP and at start of treatment was 3.6 ± 0.74 years (range 2.7–4.3 years) and 4.7 ± 1.2 years (range 3.5–6.5 years), respectively. All had an advanced BA (mean 8.0 ± 2.4 years, range 6–12 years) at diagnosis. The mean BA advancement at diagnosis and at 3 years of treatment was 3.2 ± 1.3 years (range 2.4–5.5 years) and 2.0 ± 0.35 years (range 1.5–2.5 years), respectively; the slowing of BA advancement was statistically insignificant (P-value 0.08). Four underwent GnRH stimulation test. The mean baseline and stimulated peak LH values were 0.4 ± 0.55 IU/L (range 0.1–1.23 IU/L) and 5.6 ± 0.52 IU/L (range 5.0–6.2 IU/L), respectively. All children received oral hydrocortisone (8–15 mg/m2) and fludrocortisone. Depot leuprolide (initiated at 3.75 mg per month or 11.25 mg 3 monthly) was titrated according to LH values in follow-up. All children were followed up at 6 monthly intervals for at least 3 years. The mean height velocity (HV) and the mean unstimulated serum LH concentrations before and during 1st, 2nd, and 3rd years of therapy were 8.2 ± 0.5, 6.9 ± 1.7, 7.7 ± 1.0, and 7.6 ± 1.7 cm, and 1.4 ± 2.4, 0.21 ± 0.1, 1.4 ± 2.3, and 0.41 ± 0.1 IU/L, respectively. The improvement in mean predicted adult height (PAH) from the start to completion of 3 years of therapy was statistically significant (142.2 ± 6.3 cm vs 150.4 ± 4.2 cm, P value 0.04). Regression in testicular size and breast size was observed. The mean duration of follow up was 4.2 ± 1.6 years. GnRHa therapy suppresses gonadotropin levels, stabilizes secondary sexual characteristics, and decreases rate of linear growth and BA maturation.[4] These effects were observed in our patients also. However, the treatment outcomes appear to be different as compared to patients treated in the developed countries.[45] Although our patients showed slowing down of BA advancement, the HV did not decrease significantly after GnRHa therapy in contrast with data from developed countries.[45] Additionally, the improvement in PAH barely reached statistical significance after 3 years of therapy. The lack of significant benefits of GnRHa therapy can be attributed to several factors peculiar to our setup such as delays in diagnosis of CAH due to lack of newborn screening, poor metabolic control, and late presentations with CPP.[2] The mean delay in seeking treatment exceeded 1 year in our patients that probably caused significant BA advancement. It is well-known that BA at initiation of GnRHa therapy is the most important factor that affects HV.[5] Delays in diagnosis and initiation of GnRHa therapy adversely affect height outcomes in CAH complicated by CPP in resource-limited setups. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Dayal et al retrospectively reviewed five patients (four girls and one boy) with GDPP and CAH who received GnRHa therapy. The treatment showed positive effects, such as stabilising secondary sexual characteristics and improving predicted adult height.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“In such settings, delays in seeking treatment and initiating GnRHa therapy may adversely affect height outcomes in CAH with GDPP.”
From Congenital adrenal hyperplasia complicated by gonadotropin-dependent precocious puberty (2024) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pescovitz, O. H., Comite, F., Hench, K., Barnes, K., McNemar, A., Foster, C., Kenigsberg, D., Lynn Loriaux, D., & Cutler, G. B. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80767-3 · Cited by 203
Congenital Adrenal Hyperplasia
Witchel, S. F. (2017) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2017.04.001 · Cited by 184
Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2011) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2010.10.001 · Cited by 161
Dutta, D., Kumar, M., & Mukhopadhyay, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.149316 · Cited by 50
Güven, A., Cebeci, A. N., & Hancili, S. (2015) · HORMONES · doi:10.14310/horm.2002.1555 · Cited by 39
Congenital Adrenal Hyperplasia: Issues in Diagnosis and Treatment in Children
Sharma, R., & Seth, A. (2013) · The Indian Journal of Pediatrics · doi:10.1007/s12098-013-1280-8 · Cited by 31
Congenital Adrenal Hyperplasia
Mallappa, A., & Merke, D. P. (2017) · Management of Adrenal Masses in Children and Adults · doi:10.1007/978-3-319-44136-8_11 · Cited by 8
Cited by
Adult height of children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Tsai, M.-J. M., Tsai, W., Lee, C.-T., Liu, S., Chien, Y., & Tung, Y. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.09.007 · Cited by 11
Etiological Spectrum of Precocious Puberty: Data from Northwest India
Dayal, D., Yadav, J., Seetharaman, K., Aggarwal, A., & Kumar, R. (2020) · Indian Pediatrics · doi:10.1007/s13312-020-1705-1 · Cited by 11
Self-citationSaraf, S., Srivastava, P., Panigrahi, I., Seenappa, V., Kumar, R., Yadav, J., Daniel, R., & Dayal, D. (2022) · The Indian Journal of Pediatrics · doi:10.1007/s12098-021-03975-3 · Cited by 10
Self-citationChen, H., Mo, C., & Zhong, L. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01494-0 · Cited by 10
Liu, X., Liu, F., Qi, Y., Han, X., Ma, S., & Zheng, R. (2025) · BMC Pediatrics · doi:10.1186/s12887-025-05703-8 · Cited by 6
Metadata
- Authors
- Dayal, D., Aggarwal, A., Seetharaman, K., & Muthuvel, B.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Corresponding author
- Dayal, Devi
- Venue
- Indian Journal of Endocrinology and Metabolism
- Published
- 2018-11
- Volume
- 22
- Issue
- 6
- Pages
- 858-859
- ISSN
- 2230-8210 (ISSN-L)
- 2230-9500
- PMC
- PMC6330870
- OpenAlex
- W2903512384
- Cited by
- 14
- References
- 7
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Indian Journal of Endocrinology and Metabolism (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- central precocious puberty, congenital adrenal hyperplasia, GnRH analogues, leuprolide, short stature, cortisol, fludrocortisone, GnRH stimulation test, puberty suppression, resource-limited settings, North India, salt-wasting CAH
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.